Developing siRNA therapies to address osteoporosis.
Developing siRNA therapies to address osteoporosis.
复制标题
DOI：
10.4155/tde.13.85
复制
发表时间：
2013-10
影响因子：
4.2
通讯作者：
Grainger DW
中科院分区：
文献类型：
--
作者：
Wang Y;Grainger DW
骨质疏松症是一种以骨密度低和组织结构恶化为特征的骨骼系统病理学。这种疾病与高骨折风险有关，严重影响生活质量。随着世界范围内寿命的延长，骨质疏松症的发病率变得越来越重要。然而，由于各种原因，目前治疗骨质疏松症的方法不能也不能以最理想的方式治疗该疾病。大量的研究寻求发现新的靶点和新的治疗方法。在这篇综述中，新出现的可能的RNAi介导的治疗骨质疏松症的机会，确定和相关的挑战进行了讨论。描述了能够更可靠和有效地递送到骨骼组织的靶向递送策略，以及用siRNA处理骨形成细胞以产生基于细胞的疗法的可能性。
Osteoporosis is a skeletal system pathology characterized by low bone mineral density and tissue structural deterioration. This malady is associated with high fracture risk that severely compromises quality of life. Osteoporosis incidence is becoming more significant with increasing lifespan worldwide. However, current approaches for treating osteoporosis cannot and do not treat the disease in the most ideal manner for diverse reasons. Substantial research has sought both the discovery of new targets and new therapies. In this review, emerging possible RNAi-mediated therapeutic opportunities for osteoporosis are identified and associated challenges discussed. Targeted delivery strategies capable of more reliable and efficient delivery to skeletal tissue are described, as well as possibilities to treat bone-forming cells with siRNA to produce cell-based therapy.